top of page

Get Molecular Testing - Ontario

As of July 1st, 2024, Ontario patients living with cholangiocarcinoma will be able to access molecular testing from UHN’s Laboratory Medicine Program (UHN-LMP), in partnership with the C3. UHN-LMP uses a “Custom Solid Tumour (CST) v1 Panel”, which can detect FGFR2 fusions and additional DNA/RNA biomarkers (see below for full list).

 

Patients and treating physician will receive a complete clinical report indicating Tier I (variants of strong clinical significance) and Tier II (variants of potential clinical significance) alterations in DNA and RNA biomarkers.

​

To be eligible for C3 funded testing, the patient must be a member of the C3 and physicians must submit a C3 Patient Attestation form and UHN-LMP Test Requisition Form.

Important Information:

  • Patients must be a "C3 Patient Member" 

    • Please fill out the C3 Attestation form and refer your patients to fill out the C3 Intake form

  • On Page 1 of the UHN-C3 Test Requisition Form​,    you will find information on Sample Requirements

  • On Page 2 of the UHN-C3 Test Requisition Form, under "Cholangiocarcinoma", please check  the "Canadian Cholangiocarcinoma Collaborative (C3)" option and continue to complete all forms

image.png
  • Please notify the C3 about test orders by filling out the C3 notification form  

  • All completed forms (Test Requisition and C3 Attestations) should be sent with the specimen to:

    • Toronto General Hospital​
      Eaton Wing 11-444, 200 Elizabeth Street
      Toronto, Ontario, M5G 2C4
      Attn: Dr. Shamini Selvarajah

    • Please do not fax or email these forms in advance, but if you have questions about ordering please contact us

Forms for UHN-LMP x C3

Contact and Assistance Information:

Answers to FAQ

  • The patient will get a clinical grade NGS report including FGFR fusions and additional relevant BTC targets 

    • note: CCO funded testing reports only FGFR

    • See bottom of page for all targets

  • Patients need to register with C3 by contacting  c3@ohri.ca or providing permission for the C3 to contact them

  • Patients do not have to be seen at UHN in order to receive testing

image.png

*UHN-LMP provides Clinical-Grade Molecular Testing (CAP# 7175217/CLIA# 99D1106115)

UHN-LMP-C3 GENE LIST.png
  • Instagram
  • Facebook
  • Twitter
image.png
leaf-cihr-colour-en_edited.png

Le Collectif Canadien pour le cholangiocarcinome (C3) est financé par une subvention d'équipe révolutionnaire de la Société Canadienne du cancer en partenariat avec les Instituts de recherche en santé du Canada. Les fonds de la subvention pour le C3 sont gérés par l'Institut de recherche de l'Hôpital d'Ottawa, qui sert d'institut principal pour toutes les opérations collaboratives.

© 2025 www.cholangio.ca. All rights reserved.

bottom of page